

Xichun Hu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/410070/publications.pdf>

Version: 2024-02-01

89
papers

1,415
citations

430874

18
h-index

434195

31
g-index

90
all docs

90
docs citations

90
times ranked

2042
citing authors

#	ARTICLE	IF	CITATIONS
1	Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. <i>International Journal of Cancer</i> , 2014, 135, 1961-1969.	5.1	233
2	Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF- κ B pathway. <i>BMC Cancer</i> , 2014, 14, 96.	2.6	62
3	Emerging therapies for breast cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 98.	17.0	60
4	Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. <i>European Journal of Cancer</i> , 2019, 112, 57-65.	2.8	56
5	Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 U/L. <i>Tumor Biology</i> , 2016, 37, 14083-14088.	1.8	50
6	A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer. <i>Oncotarget</i> , 2017, 8, 84224-84236.	1.8	47
7	Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy. <i>Oncotarget</i> , 2015, 6, 43135-43143.	1.8	36
8	MicroRNA-320a inhibits proliferation and invasion of breast cancer cells by targeting RAB11A. <i>American Journal of Cancer Research</i> , 2015, 5, 2719-29.	1.4	32
9	Ursolic acid promotes apoptosis and mediates transcriptional suppression of CT45A2 gene expression in non-small cell lung carcinoma harbouring EGFR T790M mutations. <i>British Journal of Pharmacology</i> , 2019, 176, 4609-4624.	5.4	31
10	Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer. <i>Cell Death and Disease</i> , 2021, 12, 684.	6.3	27
11	DNA damage response inhibitors: An avenue for TNBC treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188521.	7.4	26
12	Increased Expression of CD81 in Breast Cancer Tissue is Associated with Reduced Patient Prognosis and Increased Cell Migration and Proliferation in MDA-MB-231 and MDA-MB-435S Human Breast Cancer Cell Lines In Vitro. <i>Medical Science Monitor</i> , 2018, 24, 5739-5747.	1.1	26
13	Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis. <i>Cancer Research and Treatment</i> , 2020, 52, 1059-1066.	3.0	26
14	First-in-human HER2-targeted Bispecific Antibody KNO26 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study. <i>Clinical Cancer Research</i> , 2022, 28, 618-628.	7.0	25
15	Dosing of zoledronic acid with its anti-tumor effects in breast cancer. <i>Journal of Bone Oncology</i> , 2015, 4, 98-101.	2.4	22
16	miR-331-3p Suppresses Cell Proliferation in TNBC Cells by Downregulating NRP2. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382090582.	1.9	22
17	Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1023.	2.8	22
18	Exosomal MMP-1 transfers metastasis potential in triple-negative breast cancer through PAR1-mediated EMT. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 65-81.	2.5	22

#	ARTICLE	IF	CITATIONS
19	An explorative analysis of the prognostic value of lactate dehydrogenase for survival and the chemotherapeutic response in patients with advanced triple-negative breast cancer. <i>Oncotarget</i> , 2018, 9, 10714-10722.	1.8	20
20	Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer. <i>International Journal of Nanomedicine</i> , 2014, 9, 1443.	6.7	19
21	Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment. <i>Tumor Biology</i> , 2017, 39, 101042831771103.	1.8	19
22	Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial. <i>BMC Cancer</i> , 2018, 18, 1019.	2.6	19
23	Phase I Trial of a Novel Anti-HER2 Antibody-Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4212-4221.	7.0	19
24	Pretreatment 18F-FDG Uptake Heterogeneity Predicts Treatment Outcome of First-Line Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer. <i>Oncologist</i> , 2018, 23, 1144-1152.	3.7	18
25	Development and Validation of a Prognostic Nomogram for Hypopharyngeal Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 696952.	2.8	18
26	Bone metastasis pattern of cancer patients with bone metastasis but no visceral metastasis. <i>Journal of Bone Oncology</i> , 2019, 15, 100219.	2.4	17
27	Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial. <i>Annals of Translational Medicine</i> , 2019, 7, 482-482.	1.7	17
28	KMT5A-methylated SNIP1 promotes triple-negative breast cancer metastasis by activating YAP signaling. <i>Nature Communications</i> , 2022, 13, 2192.	12.8	17
29	Challenges in anticancer drug R&D in China. <i>Lancet Oncology</i> , The, 2019, 20, 183-186.	10.7	16
30	Clinicopathological characteristics and survival outcomes in breast carcinosarcoma: A SEER population-based study. <i>Breast</i> , 2020, 49, 157-164.	2.2	15
31	Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018). <i>Cancer</i> , 2020, 126, 3867-3882.	4.1	15
32	Phase II study of chidamide in combination with cisplatin in patients with metastatic triple-negative breast cancer. <i>Annals of Palliative Medicine</i> , 2021, 10, 11255-11264.	1.2	13
33	VPS52 induces apoptosis via cathepsin D in gastric cancer. <i>Journal of Molecular Medicine</i> , 2017, 95, 1107-1116.	3.9	12
34	A randomized multicenter phase II trial of mecapegfilgrastim single administration versus granulocyte colony-stimulating growth factor on treating chemotherapy-induced neutropenia in breast cancer patients. <i>Annals of Translational Medicine</i> , 2019, 7, 196-196.	1.7	12
35	Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial. <i>Investigational New Drugs</i> , 2020, 38, 507-514.	2.6	12
36	GSTT1, GSTP1, and GSTM1 genetic variants are associated with survival in previously untreated metastatic breast cancer. <i>Oncotarget</i> , 2017, 8, 105905-105914.	1.8	12

#	ARTICLE	IF	CITATIONS
37	Phase II Study of <i>Pseudomonas aeruginosa</i> -Mannose-Sensitive Hemagglutinin in Combination with Capecitabine for Her-2 ⁺ Negative Metastatic Breast Cancer Pretreated with Anthracycline and Taxane. <i>PLoS ONE</i> , 2015, 10, e0118607.	2.5	11
38	Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Journal of Cancer</i> , 2020, 11, 7127-7136.	2.5	11
39	The function of SOX2 in breast cancer and relevant signaling pathway. <i>Pathology Research and Practice</i> , 2020, 216, 153023.	2.3	11
40	Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study. <i>Oncotarget</i> , 2017, 8, 59810-59822.	1.8	11
41	High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy. <i>OncoTargets and Therapy</i> , 2015, 9, 117.	2.0	10
42	Fluoroquinolone resistance in bacteremic and low risk febrile neutropenic patients with cancer. <i>BMC Cancer</i> , 2015, 15, 42.	2.6	10
43	Prevalence, trend and disparities of palliative care utilization among hospitalized metastatic breast cancer patients who received critical care therapies. <i>Breast</i> , 2020, 54, 264-271.	2.2	10
44	Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study. <i>Oncotarget</i> , 2016, 7, 50643-50655.	1.8	10
45	Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial. <i>Investigational New Drugs</i> , 2022, 40, 330-339.	2.6	10
46	Malic Enzyme 1 Indicates Worse Prognosis in Breast Cancer and Promotes Metastasis by Manipulating Reactive Oxygen Species. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 8735-8747.	2.0	9
47	Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110205.	3.2	9
48	Heterogeneity derived from ¹⁸ F-FDG PET/CT predicts immunotherapy outcome for metastatic triple-negative breast cancer patients. <i>Cancer Medicine</i> , 2022, 11, 1948-1955.	2.8	9
49	Gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy with sandwiched radiotherapy in the treatment of newly diagnosed stage IE/IIIE extranodal natural killer/T-cell lymphoma, nasal type. <i>Cancer Medicine</i> , 2019, 8, 3349-3358.	2.8	8
50	Comparison of 4th ESO-ESMO international consensus guidelines for advance breast cancer and Chinese anti-cancer association committee of Breast Cancer Society guideline. <i>Breast</i> , 2019, 45, 36-42.	2.2	8
51	A risk stratification model for predicting brain metastasis and brain screening benefit in patients with metastatic triple-negative breast cancer. <i>Cancer Medicine</i> , 2020, 9, 8540-8551.	2.8	8
52	Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China. <i>Medical Science Monitor</i> , 2020, 26, e927187.	1.1	8
53	Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study. <i>Frontiers in Oncology</i> , 2022, 12, 775081.	2.8	8
54	Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0133133.	2.5	7

#	ARTICLE	IF	CITATIONS
55	PDGFD induces ibrutinib resistance of diffuse large B“cell lymphoma through activation of EGFR. <i>Molecular Medicine Reports</i> , 2020, 21, 2209-2219.	2.4	7
56	Everolimus-Related Pneumonitis in Patients with Metastatic Breast Cancer: Incidence, Radiographic Patterns, and Relevance to Clinical Outcome. <i>Oncologist</i> , 2021, 26, e580-e587.	3.7	7
57	Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 1797-1809.	1.8	7
58	Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 741142.	2.8	7
59	A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients. <i>Molecular Cancer</i> , 2022, 21, 22.	19.2	7
60	Sentinel node theory helps tracking of primary lesions of cancers of unknown primary. <i>BMC Cancer</i> , 2020, 20, 639.	2.6	6
61	Anticancer drug Rɪmp;D landscape in China. <i>Journal of Hematology and Oncology</i> , 2020, 13, 51.	17.0	6
62	Development and validation of a nomogram for predicting overall survival of patients with cancer of unknown primary: a real-world data analysis. <i>Annals of Translational Medicine</i> , 2021, 9, 198-198.	1.7	6
63	Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells. <i>Cancer Cell International</i> , 2014, 14, 107.	4.1	5
64	Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study. <i>Clinical Breast Cancer</i> , 2019, 19, e452-e458.	2.4	5
65	Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation“wide multicenter study. <i>Cancer Medicine</i> , 2021, 10, 6744-6761.	2.8	5
66	Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110228.	3.2	5
67	Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer. <i>Scientific Reports</i> , 2019, 9, 3563.	3.3	4
68	Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study. <i>Scientific Reports</i> , 2019, 9, 1710.	3.3	4
69	Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real“world study for patients with hormone receptor“positive and HER2“negative advanced breast cancer. <i>Cancer Medicine</i> , 2020, 9, 8821-8831.	2.8	4
70	Baseline monocyte and its classical subtype may predict efficacy of PD-1/PD-L1 inhibitor in cancers. <i>Bioscience Reports</i> , 2021, 41, .	2.4	4
71	Functional consequences of a rare missense BARD1 c.403G&gt;A germline mutation identified in a triple-negative breast cancer patient. <i>Breast Cancer Research</i> , 2021, 23, 53.	5.0	4
72	Loss of polarity protein Par3 is mediated by transcription factor Sp1 in breast cancer. <i>Biochemical and Biophysical Research Communications</i> , 2021, 561, 172-179.	2.1	4

#	ARTICLE	IF	CITATIONS
73	Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China. <i>Medical Science Monitor</i> , 2020, 26, e927187.	1.1	4
74	<p>Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a â€œPET biopsyâ€•method</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 6019-6027.	1.9	3
75	Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 719-726.	2.5	3
76	<p>Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience</p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 607-615.	2.0	3
77	A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers. <i>Targeted Oncology</i> , 2021, 16, 177-187.	3.6	3
78	Time to raise the bar: Transition rate of phase 1 programs on anticancer drugs. <i>Cancer Cell</i> , 2022, 40, 233-235.	16.8	3
79	Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China. <i>Frontiers in Oncology</i> , 2020, 10, 599604.	2.8	2
80	Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HRâ€™+â€™/HER2- advanced breast cancer. <i>Investigational New Drugs</i> , 2021, 39, 1549-1558.	2.6	2
81	A case report of advanced thymoma re-treated with PD-1 inhibitor after initial immune-related pneumonitis. <i>Annals of Palliative Medicine</i> , 2021, 10, 10083-10090.	1.2	2
82	Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer. <i>Oncotarget</i> , 2017, 8, 79527-79536.	1.8	2
83	Polarity protein Par3 sensitizes breast cancer to paclitaxel by promoting cell cycle arrest. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 75-87.	2.5	2
84	Abstract PD8-04: Safety and anti-tumor activity of ARX788 in HER2-positive metastatic breast cancer patients whose disease is resistant/refractory to HER2 targeted agents (trastuzumab, ADCs, TKIs, and Tj ETQq0 0 OrgBT /Overlock 10 T		
85	Abstract P2-13-43: Preclinical and early clinical safety and pharmacokinetics data of DZD1516, an BBB-penetrant selective HER2 inhibitor for the treatment of HER2 positive metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P2-13-43-P2-13-43.	0.9	2
86	Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases. <i>BMC Cancer</i> , 2021, 21, 1174.	2.6	1
87	Case Report: Molecular Profiling Assists in the Diagnosis and Treatment of Cancer of Unknown Primary. <i>Frontiers in Oncology</i> , 2022, 12, 723140.	2.8	1
88	An integrated bioinformatics analysis to investigate the targets of miR-133a-1 in breast cancer. <i>Translational Cancer Research</i> , 2021, 10, 1238-1248.	1.0	0
89	The CDK4/6 inhibitor FCN-437c plus letrozole for the treatment of HR+/HER2â€™ advanced breast cancer: Updated results from a phase 1b study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e13025-e13025.	1.6	0